Health
STAT+: Newer GLP-1 drugs to combat obesity may be the next global battleground over access to medicines, expert warns
Publication: STAT
Author: Ed Silverman
Source published: 16/11/2026, 18:18:25 UTC
Briefing created: 17/11/2026, 13:54:24 UTC
Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 17/11/2026, 13:51:26 UTC.
Briefings
Experts warn that while newer GLP-1 obesity drugs are being developed, access to these medicines could soon become a major conflict in lower-income countries. Ken Shadlen, an LSE professor, notes that generic versions of semaglutide (Wegovy) are already available in some nations, but the pharmaceutical industry is racing to create even more effective and safer alternatives. This development highlights a potential future battleground over medicine access, though current data does not confirm widespread availability of these newer drugs globally.
Key points
- Ken Shadlen, an LSE professor studying pharmaceutical politics, warns that newer GLP-1 drugs could become a major access battleground in lower-income countries.
- Generic versions of semaglutide (Wegovy) are already available in some nations, but the industry is racing to develop even more effective and safer alternatives.
Context
Ken Shadlen, an LSE professor, discusses the looming challenges of pharmaceutical access. The conversation is an edited version of a discussion with STAT+ reporters.
Limitations
Current evidence does not confirm widespread availability of newer GLP-1 drugs globally. The article is an edited version of a conversation with STAT+ reporters, and the full story is not available.
Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 17/11/2026, 13:54:24 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.
View archived briefing on IPFS
bafybeifixqmym7qrxp52wv3pqvbw62nvwf3oyodiv2rxntzosnfuwte5t4